Skip to search form
Skip to main content
>
Semantic Scholar
Semantic Scholar's Logo
Search
Sign In
Create Free Account
You are currently offline. Some features of the site may not work correctly.
Multiple Sclerosis, Relapsing-Remitting
Known as:
Remitting Relapsing Multiple Sclerosis
, Relapsing Remitting Multiple Sclerosis
, Multiple Sclerosis, Remitting-Relapsing
Expand
The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial…
Expand
National Institutes of Health
Create Alert
Related topics
Related topics
10 relations
Glatiramer
In Blood
Microbiological
Multiple Sclerosis, Acute Relapsing
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Nrf2 at the heart of oxidative stress and cardiac protection.
Qin M Chen
,
A. Maltagliati
Physiological genomics
2018
Corpus ID: 3476860
The NFE2L2 gene encodes the transcription factor Nrf2 best known for regulating the expression of antioxidant and detoxification…
Expand
Review
2018
Review
2018
The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives.
A. Huwiler
,
U. Zangemeister-Wittke
Pharmacology & therapeutics
2018
Corpus ID: 207366286
The immunomodulatory drug fingolimod (FTY720, GilenyaR) was approved for oral treatment of relapsing-remitting multiple sclerosis…
Expand
Highly Cited
2012
Highly Cited
2012
Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial
J. Cohen
,
A. Coles
,
D. Arnold
,
C. Confavreux
,
F. T. C. I. investigators
The Lancet
2012
Corpus ID: 15841906
BACKGROUND The anti-CD52 monoclonal antibody alemtuzumab reduced disease activity in a phase 2 trial of previously untreated…
Expand
Highly Cited
2010
Highly Cited
2010
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
L. Kappos
,
E. Radue
,
+8 authors
P. Burtin
The New England journal of medicine
2010
Corpus ID: 20306348
BACKGROUND Oral fingolimod, a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes…
Expand
Highly Cited
2010
Highly Cited
2010
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
J. Cohen
,
F. Barkhof
,
+14 authors
L. Kappos
The New England journal of medicine
2010
Corpus ID: 205091527
BACKGROUND Fingolimod (FTY720), a sphingosine-1-phosphate-receptor modulator that prevents lymphocyte egress from lymph nodes…
Expand
Highly Cited
2008
Highly Cited
2008
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.
S. Hauser
,
E. Waubant
,
+9 authors
C. H. Smith
The New England journal of medicine
2008
Corpus ID: 38840028
BACKGROUND There is increasing evidence that B lymphocytes are involved in the pathogenesis of multiple sclerosis, and they may…
Expand
Highly Cited
2003
Highly Cited
2003
A controlled trial of natalizumab for relapsing multiple sclerosis.
D. Miller
,
O. Khan
,
+7 authors
P. O'Connor
The New England journal of medicine
2003
Corpus ID: 43237123
BACKGROUND In patients with multiple sclerosis, inflammatory brain lesions appear to arise from autoimmune responses involving…
Expand
Highly Cited
2002
Highly Cited
2002
Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial
H. Hartung
,
R. Gonsette
,
N. Konig
,
H. Kwiecinski
,
the Mitoxantrone in Multiple Sclerosis Study Group
The Lancet
2002
Corpus ID: 2437130
BACKGROUND Treatment options for patients with secondary progressive multiple sclerosis are few. Encouraging results in open…
Expand
Highly Cited
2001
Highly Cited
2001
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis
W. Mcdonald
,
A. Compston
,
+13 authors
J. Wolinsky
Annals of neurology
2001
Corpus ID: 13870943
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on…
Expand
Highly Cited
2000
Highly Cited
2000
Relapses and progression of disability in multiple sclerosis.
C. Confavreux
,
S. Vukusic
,
T. Moreau
,
P. Adeleine
The New England journal of medicine
2000
Corpus ID: 31087694
BACKGROUND The influence of the patterns of onset of multiple sclerosis and relapses of the disease on the time course of…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE